{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/85223"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/85223","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"In Vitro Effects of Actively Delivered Coencapsulated Curcumin and Cisplatin Nanoliposomes on Squamous Oral Carcinoma","abstract":"Multidrug carriers were also formulated using a Dipalmitoyl Phosphatidylcholine (DPPC) as a primary lipid, with incorporation of a lysolipid to achieve controlled release of the drugs loaded within. Diagnostic ultrasound energy was then employed as a tool to achieve controlled release from the newly developed multidrug carriers at a frequency of 7.5 MHz and four different power intensities depending on the pulse repetition time. The optimal lipid composition and the intensity settings of ultrasound energy were chosen to formulate a new class of nanoliposomes---ultrasound sensitive nanoliposomes (USNL). The USNLs released increasing amounts of drug in response to increasing irradiation times while the drug release was not significant when the Non-USNLs were exposed to ultrasound energy levels. In vitro studies to test the cytotoxicity of the formulations showed that the USNLs significantly inhibited cell survival of SCC9 oral cancer cells, as compared to the Non-USNLs. We hypothesize that the drug is released due to increased membrane permeability during exposure to ultrasound energy. The lipid composition and energy levels play a key role in determining the efficacy of diagnostic ultrasound energy as a tool for drug delivery. Thus the novel chemotherapeutic approach with the use of compound liposomes, when combined with an active delivery modality can be employed as the primary treatment rather then opting for cosmetically harsh surgery. This may also help in better organ preservation and functioning, which in turn would improve the overall quality of life in patients with these tumors.","abstract_html":"Multidrug carriers were also formulated using a Dipalmitoyl Phosphatidylcholine (DPPC) as a primary lipid, with incorporation of a lysolipid to achieve controlled release of the drugs loaded within. Diagnostic ultrasound energy was then employed as a tool to achieve controlled release from the newly developed multidrug carriers at a frequency of 7.5 MHz and four different power intensities depending on the pulse repetition time. The optimal lipid composition and the intensity settings of ultrasound energy were chosen to formulate a new class of nanoliposomes---ultrasound sensitive nanoliposomes (USNL). The USNLs released increasing amounts of drug in response to increasing irradiation times while the drug release was not significant when the Non-USNLs were exposed to ultrasound energy levels. In vitro studies to test the cytotoxicity of the formulations showed that the USNLs significantly inhibited cell survival of SCC9 oral cancer cells, as compared to the Non-USNLs. We hypothesize that the drug is released due to increased membrane permeability during exposure to ultrasound energy. The lipid composition and energy levels play a key role in determining the efficacy of diagnostic ultrasound energy as a tool for drug delivery. Thus the novel chemotherapeutic approach with the use of compound liposomes, when combined with an active delivery modality can be employed as the primary treatment rather then opting for cosmetically harsh surgery. This may also help in better organ preservation and functioning, which in turn would improve the overall quality of life in patients with these tumors.","abstract_has_math":false,"creators":["Gosangari, Saujanya Laxmirajam"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Speech and Hearing Science","degree_department":null,"school":null,"contributors":["Kenneth L. Watkin"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-09-25T22:36:13Z","date_published":"2015-09-25T22:36:13Z","updated_at":"2026-07-22T22:26:24Z","subjects":["Health Sciences, Pharmacy"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["(MiAaPQ)AAI3337994"],"render_values":[{"text":"(MiAaPQ)AAI3337994","href":null,"code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/2142/85223","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Kenneth L. Watkin"]},{"key":"dc:creator","label":"Author","values":["Gosangari, Saujanya Laxmirajam"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015-09-25T22:36:13Z","10000-01-01","2008"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Speech and Hearing Science"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Health Sciences, Pharmacy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/85223","(MiAaPQ)AAI3337994"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Multidrug carriers were also formulated using a Dipalmitoyl Phosphatidylcholine (DPPC) as a primary lipid, with incorporation of a lysolipid to achieve controlled release of the drugs loaded within. Diagnostic ultrasound energy was then employed as a tool to achieve controlled release from the newly developed multidrug carriers at a frequency of 7.5 MHz and four different power intensities depending on the pulse repetition time. The optimal lipid composition and the intensity settings of ultrasound energy were chosen to formulate a new class of nanoliposomes---ultrasound sensitive nanoliposomes (USNL). The USNLs released increasing amounts of drug in response to increasing irradiation times while the drug release was not significant when the Non-USNLs were exposed to ultrasound energy levels. In vitro studies to test the cytotoxicity of the formulations showed that the USNLs significantly inhibited cell survival of SCC9 oral cancer cells, as compared to the Non-USNLs. We hypothesize that the drug is released due to increased membrane permeability during exposure to ultrasound energy. The lipid composition and energy levels play a key role in determining the efficacy of diagnostic ultrasound energy as a tool for drug delivery. Thus the novel chemotherapeutic approach with the use of compound liposomes, when combined with an active delivery modality can be employed as the primary treatment rather then opting for cosmetically harsh surgery. This may also help in better organ preservation and functioning, which in turn would improve the overall quality of life in patients with these tumors.","Made available in DSpace on 2015-09-25T22:36:13Z (GMT). No. of bitstreams: 2 license.txt: 4848 bytes, checksum: 96035ab3f5e1c23cc7138a224ce498bd (MD5) 3337994.pdf: 1218911 bytes, checksum: 71da55b53e5fe3b04ce98d92cf18ef66 (MD5) Previous issue date: 2008","Embargo set by: Seth Robbins for item 86504 Lift date: Forever Reason: Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","U of I Only","77 p.","Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 2008."]},{"key":"dc:title","label":"Title","values":["In Vitro Effects of Actively Delivered Coencapsulated Curcumin and Cisplatin Nanoliposomes on Squamous Oral Carcinoma"]}]}],"canonical_facts":{"dc:contributor":["Kenneth L. Watkin"],"dc:creator":["Gosangari, Saujanya Laxmirajam"],"dc:date":["2015-09-25T22:36:13Z","10000-01-01","2008"],"dc:description":["Multidrug carriers were also formulated using a Dipalmitoyl Phosphatidylcholine (DPPC) as a primary lipid, with incorporation of a lysolipid to achieve controlled release of the drugs loaded within. Diagnostic ultrasound energy was then employed as a tool to achieve controlled release from the newly developed multidrug carriers at a frequency of 7.5 MHz and four different power intensities depending on the pulse repetition time. The optimal lipid composition and the intensity settings of ultrasound energy were chosen to formulate a new class of nanoliposomes---ultrasound sensitive nanoliposomes (USNL). The USNLs released increasing amounts of drug in response to increasing irradiation times while the drug release was not significant when the Non-USNLs were exposed to ultrasound energy levels. In vitro studies to test the cytotoxicity of the formulations showed that the USNLs significantly inhibited cell survival of SCC9 oral cancer cells, as compared to the Non-USNLs. We hypothesize that the drug is released due to increased membrane permeability during exposure to ultrasound energy. The lipid composition and energy levels play a key role in determining the efficacy of diagnostic ultrasound energy as a tool for drug delivery. Thus the novel chemotherapeutic approach with the use of compound liposomes, when combined with an active delivery modality can be employed as the primary treatment rather then opting for cosmetically harsh surgery. This may also help in better organ preservation and functioning, which in turn would improve the overall quality of life in patients with these tumors.","Made available in DSpace on 2015-09-25T22:36:13Z (GMT). No. of bitstreams: 2 license.txt: 4848 bytes, checksum: 96035ab3f5e1c23cc7138a224ce498bd (MD5) 3337994.pdf: 1218911 bytes, checksum: 71da55b53e5fe3b04ce98d92cf18ef66 (MD5) Previous issue date: 2008","Embargo set by: Seth Robbins for item 86504 Lift date: Forever Reason: Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","Restricted to the U of I community idenfinitely during batch ingest of legacy ETDs","U of I Only","77 p.","Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 2008."],"dc:identifier":["http://hdl.handle.net/2142/85223","(MiAaPQ)AAI3337994"],"dc:language":["eng"],"dc:subject":["Health Sciences, Pharmacy"],"dc:title":["In Vitro Effects of Actively Delivered Coencapsulated Curcumin and Cisplatin Nanoliposomes on Squamous Oral Carcinoma"],"dc:type":["text"],"thesis:degree_discipline":["Speech and Hearing Science"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:26:24Z"}